The estimated Net Worth of Alfonso Quintas Cardama is at least $4.13 Milión dollars as of 9 December 2022. Alfonso Cardama owns over 13,799 units of TCR2 Therapeutics stock worth over $161,999 and over the last 6 years he sold TCRR stock worth over $35,342. In addition, he makes $3,930,570 as Chief Medical Officer at TCR2 Therapeutics.
Alfonso has made over 5 trades of the TCR2 Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 13,799 units of TCRR stock worth $15,179 on 9 December 2022.
The largest trade he's ever made was exercising 95,385 units of TCR2 Therapeutics stock on 1 December 2022 worth over $141,170. On average, Alfonso trades about 11,173 units every 31 days since 2019. As of 9 December 2022 he still owns at least 109,459 units of TCR2 Therapeutics stock.
You can see the complete history of Alfonso Cardama stock trades at the bottom of the page.
Dr. Alfonso Quintas Cardama M.D. serves as Chief Medical Officer of the Company. Dr. Quintás was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, he served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine—Yeshiva University and a hematology and oncology fellowship and a leukemia fellowship at The University of Texas, MD Anderson Cancer Center.
As the Chief Medical Officer of TCR2 Therapeutics, the total compensation of Alfonso Cardama at TCR2 Therapeutics is $3,930,570. There are 1 executives at TCR2 Therapeutics getting paid more, with Garry Menzel having the highest compensation of $8,482,210.
Alfonso Cardama is 49, he's been the Chief Medical Officer of TCR2 Therapeutics since 2017. There are 11 older and 5 younger executives at TCR2 Therapeutics. The oldest executive at TCR2 Therapeutics Inc. is Neil Gibson, 63, who is the Independent Director.
Alfonso's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at TCR2 Therapeutics have traded over $15,820,150 worth of TCR2 Therapeutics stock and bought 4,788,512 units worth $65,684,711 . The most active insiders traders include Group, Llc Green Jeremy Red..., Kevin Ctang Capital Managem... a Ansbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $229,829. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth $86,000.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
TCR2 Therapeutics executives and other stock owners filed with the SEC include: